Seminars in Oncology
Volume 29, Issue 2 , Pages 126-135 , April 2002

Intrahepatic arterial infusion of chemotherapy: Clinical results

References 

  1. Ferlay J, Bray F, Pisani P, et al.  GLOBOCAN 2000: Cancer Incidence, Mortality, and Prevalence Worldwide, version 1.0.. International Agency for Research on Cancer (IARC) Cancerbase, No. 5. Lyon, France: IARC Press; 2001;
  2. a. Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol. 1976;2:285–288
  3. Jaffe BM, Donegan WL, Watson F, et al.  Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet. 1968;127:1–11
  4. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. II. The prognosis for patients with hepatic metastases from gastric carcinoma verified by laparotomy and postmortem examination. Digestion. 1969;2:179–186
  5. Goslin R, Steele G, Zamcheck N, et al.  Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum. 1982;25:749–754
  6. Bengtsson G, Carlsson G, Hafstrom L, et al.  Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141:586–589
  7. Finan PJ, Marshall RJ, Cooper EH, et al.  Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: A clinical and computer analysis. Br J Surg. 1985;72:373–377
  8. de Brauw LM, van de Velde CJ, Bouwhuis-Hoogerwerf ML, et al.  Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol. 1987;34:81–86
  9. Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver. Optimizing the results of treatment. Surg Clin North Am. 1989;69:339–359
  10. Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg. 1989;210:127–138
  11. Iwatsuki S, Esquivel CO, Gordon RD, et al.  Liver resection for metastatic colorectal cancer. Surgery. 1986;100:804–810
  12. Nordlinger B, Quilichini MA, Parc R, et al.  Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg. 1987;205:256–263
  13. Fong Y, Fortner J, Sun RL, et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–321
  14. Nordlinger B, Guiguet M, Vaillant JC, et al.  Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254–1262
  15. Baker LH, Tulley RW, Blumgart L. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol. 1976;2:285–288
  16. Scheele J, Stangl R, Altendorf-Hofmann A, et al.  Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13–29
  17. van Ooijen B, Wiggers T, Meijer S, et al.  Hepatic resections for colorectal metastases in The Netherlands. A multiinstitutional 10-year study. Cancer. 1992;70:28–34
  18. Fegiz G, Ramacciato G, Gennari L, et al.  Hepatic resections for colorectal metastases: The Italian multicenter experience. J Surg Oncol. 1991;2:144–154 (suppl)
  19. Cady B, Stone MD, McDermott WV, et al.  Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg. 1992;127:561–569
  20. Breedis C, Young C. Blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969
  21. Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983;10:176–182
  22. Yasuda S, Noto T, Ikeda M, et al.  Hepatic arterial infusion chemotherapy using implantable reservoir in colorectal liver metastasis. Gan To Kagaku Ryoho. 1990;17:1815–1819
  23. Kemeny N, Sigurdon E. Intra-arterial chemotherapy for liver tumors. In: ed 2.  Blumgart L editors. Surgery of the Liver and Biliary Tract. New York, NY: Churchill Livingstone; 1994;p. 1458–1491
  24. Kemeny N, Daly J, Reichman B, et al.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107:459–465
  25. Hohn DC, Stagg RJ, Friedman MA, et al.  A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol. 1989;7:1646–1654
  26. Chang AE, Schneider PD, Sugarbaker PH, et al.  A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685–693
  27. Martin JK, O'Connell MJ, Wieand HS, et al.  Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg. 1990;125:1022–1027
  28. Wagman LD, Kemeny MM, Leong L, et al.  A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 1990;8:1885–1893
  29. Allen-Mersh TG, Earlam S, Fordy C, et al.  Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255–1260
  30. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18:243–254
  31. Rougier P, Laplanche A, Huguier M, et al.  Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal cancer: Long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112–1118
  32. McArdle C, Kerr DJ, Lederman J, et al.  Intravenous (IV) vs. intrahepatic arterial (IHA) 5FU/leucovorin for colorectal (CRC) liver metastases: Preliminary results of the MRC CR05/EORTC 40972 randomised trial. Proc Am Soc Clin Oncol. 2001;20:126a; (abstr)
  33. Meta-Analysis Group in Cancer . Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996;88:252–288
  34. Doci R, Gennari L, Bignami P, et al.  One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants. Br J Surg. 1991;78:797–801
  35. Scheole J. Liver resection for colorectal metastases. World J Surg. 1995;19:59–71
  36. Fong Y, Cohen AM, Fortner JG, et al.  Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–946
  37. Jamison RL, Donohue JH, Nagorney DM, et al.  Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505–511
  38. Coppa GF, Eng K, Ranson JH, et al.  Hepatic resection for metastatic colon and rectal cancer. An evaluation of preoperative and postoperative factors. Ann Surg. 1985;202:203–208
  39. Moriya Y, Sugihara K, Hojo K, et al.  Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: A pilot study. Eur J Surg Oncol. 1991;17:519–525
  40. Curley SA, Roh MS, Chase JL, et al.  Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Am J Surg. 1993;166:743–748
  41. Nonami T, Takeuchi Y, Yasui M, et al.  Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma. Semin Oncol. 1997;24(suppl 6):130–134
  42. Kemeny N, Huang Y, Cohen AM, et al.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048
  43. Kemeny MM, Goldberg D, Beatty JD, et al.  Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer. 1986;57:492–498
  44. Lorenz M, Muller HH, Schramm H, et al.  Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg. 1998;228:756–762
  45. Kemeny MM, Asak S, Lipsitz B, et al.  Results of the Intergroup (Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG) prospective randomized study of surgery alone versus continuous systemic infusion of 5-FU after hepatic resection for colorectal liver metastases. Proc Am Soc Clin Oncol. 1999;18:264a; (abstr)
  46. Giacchetti S, Itzhaki M, Gruia G, et al.  Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663–669
  47. Durand-Zaleski I, Roche B, Buyse M, et al.  Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. J Natl Cancer Inst. 1997;89:790–795
  48. Kemeny NE, Ron IG. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol. 1999;26:524–535
  49. Kemeny N, Seiter K, Niedzwiecki D, et al.  A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992;69:327–334
  50. Kemeny MM, Alava G, Oliver JM. The effects on liver metastases of circadian patterned hepatic artery infusion of FUDR. HPB Surg. 1994;7:219–224
  51. von Roemeling R, Hrushesky WJ. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol. 1989;7:1710–1719
  52. Stagg RJ, Venook AP, Chase JL, et al.  Alternating hepatic intra-arterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst. 1991;83:423–428
  53. Davidson BS, Izzo F, Chase JL, et al.  Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. Am J Surg. 1996;172:244–247
  54. Metzger U, Weder W, Rothlin M, et al.  Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. Recent Results Cancer Res. 1991;121:198–204
  55. Safi F, Bittner R, Roscher R, et al.  Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. Cancer. 1989;64:379–387
  56. O'Connell MJ, Nagorney DM, Bernath AM, et al.  Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol. 1998;16:2528–2533
  57. Gorlick R, Metzger R, Danenberg KD, et al.  Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol. 1998;16:1465–1469
  58. Leichman L, Lenz HJ, Leichman CG, et al.  Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial. Eur J Cancer. 1995;31A:1306–1310
  59. Kemeny N, Gonen M, Sullivan D, et al.  Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001;19:2687–2695
  60. Pettavel J, Gardiol D, Bergier N, et al.  Necrosis of main bile ducts caused by hepatic artery infusion of 5-fluoro-2-deoxyuridine. Reg Cancer Treat. 1988;1:83–92
  61. Kemeny MM, Battifora H, Blayney DW, et al.  Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg. 1985;202:176–181

☆ Address reprint requests to Nancy E. Kemeny, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021.

PII: S0093-7754(02)50133-0

doi: 10.1053/sonc.2002.31680

Seminars in Oncology
Volume 29, Issue 2 , Pages 126-135 , April 2002

Article Tools